ApothéCure

ApothéCure was established in Dallas, Texas, in 1991 by Gary Osborn. Its business was based on pharmacy compounding: preparing customized medicines and related nutritional products for individual patients and prescribing physicians. The company was associated with the Texas Institute of Functional Medicines as a sister corporation, placing it within a functional-medicine-oriented network. The available account does not identify a precise corporate parent, detailed ownership structure beyond Osborn's ownership, or a later successor for ApothéCure. The pharmacy first attracted regulatory scrutiny in 2004. Complaints alleged that compounded testosterone and growth hormones had been dispensed unlawfully, including to a pregnant patient. Pharmacy-board officials did not find sufficient evidence to impose discipline, but they sent the company a warning letter. Also in 2004, Pennsylvania health officials alerted healthcare providers statewide after three patients experienced reactions associated with intravenous phosphatidylcholine supplied by ApothéCure. In 2005, the company was named as a defendant or involved party in a wrongful-death case concerning a five-year-old autistic boy who died after receiving disodium EDTA as part of chelation therapy. The therapy was promoted by some practitioners for autism despite not being approved by the FDA for that use. The case added to questions around compounded products, off-label treatment, and the responsibilities of pharmacies supplying such preparations. The most consequential event occurred in 2007. Three patients in the Pacific Northwest died after receiving injectable colchicine for back pain, an off-label use associated with naturopathic treatment. A labeling error meant that the preparation was ten times more concentrated than the strength stated on its vials. The resulting doses were toxic. More than 3,500 vials distributed nationally were recalled, and families of two victims filed wrongful-death actions; the available account says those cases ended in confidential settlements, while a third family's negotiations were still ongoing at the time described. The incident triggered state enforcement. Oregon and Texas attorneys general sued ApothéCure and Osborn, alleging inadequate safety controls, improper labeling and manufacturing practices, exaggerated supplement claims, and distribution of injectable colchicine in Oregon without the necessary license. The Oregon case was settled in April 2008. Its terms included a $100,000 payment to the state, a possible $500,000 civil penalty if ApothéCure sought to sell products in Oregon again, and refunds related to 222 sales to Oregon consumers between 2004 and 2007. Federal criminal proceedings followed. In 2012, the Department of Justice charged the corporation and Osborn with two misdemeanor violations of the Federal Food, Drug and Cosmetic Act concerning the misbranding associated with the colchicine deaths. Both defendants pleaded guilty. Osborn received home detention, one year of probation, and a $100,000 fine. ApothéCure was separately placed on probation for five years and fined $100,000. Osborn founded NuVision Pharmacy in 2010, and that business began operating in 2011. NuVision was shut down in 2013. This later development is relevant to the founder's business activities but does not by itself establish that ApothéCure closed at the same time. No reliable current operating information is supplied in the reference material, so the brand's present status remains unknown.

1. 2013NuVision Pharmacy shut down

   The later pharmacy venture founded by Osborn ceased operations.

   Source
2. 2012Federal guilty pleas

   ApothéCure and Osborn pleaded guilty to misdemeanor federal drug-law violations related to the misbranded colchicine.

   Source
3. 2010Osborn founds NuVision Pharmacy

   The company's founder established a separate pharmacy venture that opened the following year.

   Source
4. 2008Oregon enforcement settlement

   ApothéCure settled Oregon attorney-general litigation involving distribution practices, refunds, and financial penalties.

   Source
5. 2007Colchicine mislabeling crisis

   Three deaths were linked to an injectable colchicine preparation whose actual concentration was ten times higher than its label stated; a nationwide recall followed.

   Source
6. 2004Regulatory scrutiny begins

   The company faced an investigation over alleged improper hormone dispensing and a health alert concerning reactions to an injectable product.

   Source
7. 1991ApothéCure founded in Dallas

   Gary Osborn founded the compounding pharmacy in Dallas, Texas.

   Source

A physician- and patient-oriented compounding pharmacy focused on customized formulations and functional-medicine-related products.

• Custom compounded formulasCompounded medicines

  ApothéCure's core offering consisted of customized pharmaceutical preparations made for individual patients or prescribed for particular clinical requirements. The reference material identifies the company broadly as a compounding pharmacy but does not provide a complete catalog, dosage range, or proprietary product names.

• Hormone compoundsCompounded medicines

  The company compounded hormone-related products, including testosterone and growth hormones. These preparations became the subject of a 2004 investigation into whether certain compounds had been dispensed illegally. The investigation did not result in pharmacy-board discipline according to the available account.

• Nutritional supplementsNutritional supplements

  ApothéCure supplied nutritional supplements to patients and physicians in connection with its functional-medicine positioning. Later state litigation alleged that the company made exaggerated claims about the benefits of some dietary supplements.

• Injectable colchicineCompounded injectable

  ApothéCure supplied injectable colchicine used by some practitioners for off-label treatment of back pain. In 2007, a concentration and labeling error resulted in vials containing ten times the stated strength, a defect associated with three deaths and a nationwide recall of more than 3,500 vials.

• 2012Enter federal guilty pleasOther

  Federal prosecutors charged the company and Gary Osborn over drug misbranding associated with the incorrectly labeled colchicine.

  What changed. ApothéCure and Osborn pleaded guilty to two misdemeanor Federal Food, Drug and Cosmetic Act violations.

  Aftermath. Osborn received home detention, one year of probation, and a $100,000 fine. The corporation received five years of probation and a separate $100,000 fine.

  Criminal fines. $100,000 fine for Osborn and $100,000 fine for ApothéCure (2012 sentencing)

  Source
• 2008Settle Oregon attorney-general litigationOther

  Oregon alleged that ApothéCure distributed injectable colchicine without the required state license and failed to meet appropriate safety, labeling, and manufacturing standards.

  What changed. The company agreed to pay Oregon $100,000, provide refunds connected with 222 prior consumer sales, and face a potential $500,000 civil penalty if it resumed sales in the state.

  Aftermath. The settlement resolved the Oregon enforcement action while separate wrongful-death and federal proceedings continued.

  Settlement payment and potential civil penalty. $100,000 payment; potential $500,000 penalty upon renewed Oregon sales (2008 settlement)

  Source

• 2012Federal misbranding caseControversy

  ApothéCure and Gary Osborn pleaded guilty to misdemeanor violations of the Federal Food, Drug and Cosmetic Act connected with the misbranded colchicine involved in the deaths.

  Source
• 2007Colchicine concentration and labeling incidentControversy

  Three patients died after receiving injectable colchicine that was ten times more concentrated than indicated on the labels. The incident prompted a nationwide recall, state lawsuits, wrongful-death claims, and later federal criminal charges.

  Source

• 2013NuVision Pharmacy shut down

  NuVision Pharmacy, founded by Osborn as a related later venture, was shut down.

  Other
  Source
• 2011NuVision Pharmacy begins operations

  Gary Osborn's NuVision Pharmacy, founded in 2010, opened for business.

  Other
  Source

1. ApothéCure